| Protein | Sphingosine kinase 1 (SPHK1) |
|---|---|
| Encoded by | [SPHK1](/genes/sphk1) |
| Catalytic reaction | Sphingosine to sphingosine-1-phosphate (S1P) |
| Core role | Lipid signaling node linking inflammation, survival, and trafficking |
| Key disease links | [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [neuroinflammation](/mechanisms/neuroinflammation) |
SPHK1 generates bioactive S1P from sphingosine, shifting sphingolipid balance away from ceramide-dominant stress signaling toward pro-survival, trafficking, and immune-modulatory signaling states.[1][2] In CNS disease contexts, SPHK1 is increasingly viewed as a tunable rheostat for microglial activation, vascular responses, and synaptic stress resilience.[3][4]
SPHK1 is a lipid kinase with conserved catalytic motifs that control ATP-dependent phosphorylation of sphingosine. Activity is shaped by membrane recruitment, phosphorylation status, and substrate pool availability, producing context-dependent bursts of S1P signaling.[2:1][5]
In healthy neural tissue, SPHK1 contributes to:
These roles interface with autophagy, endolysosomal trafficking, and vascular-neuroimmune communication.[4:1][5:1]
Sphingolipid dyshomeostasis is repeatedly observed across AD, PD, and related disorders, with SPHK1-dependent pathways linked to inflammatory tone and amyloid/tau-relevant biology.[3:2][6] Experimental work supports both harmful and compensatory SPHK1 responses depending on disease stage and cell type, indicating therapeutic benefit will likely require precision timing and compartment targeting rather than constitutive activation.[4:2][7]
Translational strategies include:
Because sphingolipid pathways regulate immune and vascular physiology, safety frameworks should monitor infection risk, vascular effects, and immune-cell redistribution when pathway-active drugs are used.
van Echten-Deckert G, Herget T. Sphingolipid metabolism in neural cells. Ann N Y Acad Sci. 2006. ↩︎ ↩︎
Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Trends Cell Biol. 2020. ↩︎ ↩︎ ↩︎
Merrill AH Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. J Neurochem. 2011. ↩︎ ↩︎ ↩︎
Sita G, Hrelia P, Graziosi A, Morroni F. Sphingosine kinase-dependent regulation of pro-resolving lipid mediators in Alzheimer's disease. Front Pharmacol. 2022. ↩︎ ↩︎ ↩︎
Takasugi N, Sasaki T, Ebinuma I, et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci. 2011. ↩︎ ↩︎
He X, Huang Y, Li B, et al. SPHK1 promotes amyloid-beta generation through autophagy dysregulation. Cell Death Dis. 2019. ↩︎
Jin Y, Li Q, Li X, et al. Sphingosine-1-phosphate: Lipid signaling in pathology and therapy. Acta Pharm Sin B. 2019. ↩︎ ↩︎
Zhou M, Li Y, Lu M, et al. The role of sphingosine-1-phosphate in the development and progression of Parkinson's disease. Front Aging Neurosci. 2023. ↩︎